Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

Authors

  • Vishal R. Tandon
  • Annil Mahajan

Keywords:

Janus kinase, Rheumatoid arthritis, Janus kinase (JAK) inhibitors, Tofacitinib, Baricitinib, Upadacitinib

Abstract

Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling has been established to have pathophysiological role in multiple disease states, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease and multiple immune-driven dermatological diseases etc. JAK inhibitors are low-molecular-weight compounds, which exert anti-rheumatic effects by suppressing the action of JAK, an intracellular tyrosine kinase. JAK inhibitors are useful mainly in a variety of cases, including patients who inadequately responded to treatment with methotrexate and/or DMARDs.

Downloads

Download data is not yet available.

Downloads

Published

10-07-2022

How to Cite

1.
Tandon VR, Mahajan A. Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. JK Science [Internet]. 2022 Jul. 10 [cited 2024 Nov. 21];24(3):143. Available from: https://journal.jkscience.org/index.php/JK-Science/article/view/134

Most read articles by the same author(s)

1 2 > >> 

Similar Articles

You may also start an advanced similarity search for this article.